HitGen (688222.SS) Stock Price

HitGen Price

CLOSED
29.05
​
Market closed

Over the last 8 years HitGen grew revenue by 33.1% annually, reaching 525.57 M CNY. Earnings per share have declined at 2.2% per year over the last 7 years. For HitGen, the net margin of 20.8% is broadly stable versus 20.4% a few years ago. At today's price the dividend yield works out to roughly 0.21%. The payout ratio is around 22% of earnings. The consensus 12-month price target for HitGen is 27.74 CNY, about 4.5% below where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

HitGen stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HitGen business model & stock analysis

HitGen Inc. generates revenue through DEL screening services, DEL library customization, chemical synthesis, and transfer of new drug R&D projects. The company serves pharmaceutical and biotechnology firms seeking to develop seed and lead compounds for drug discovery. Its domestic market focus includes clients in China, while international clients also access its DEL technology solutions. HitGen's services support the research and development phase of drug development, targeting companies in the pharmaceutical sector that require advanced compound libraries for early-stage drug discovery. The firm's DEL technology enables the creation of large compound libraries for high-throughput screening, which is critical for identifying potential drug candidates. HitGen's services are tailored to clients' needs, offering customized DEL libraries and synthesis support for drug development projects. Its business model relies on providing specialized R&D services to pharmaceutical companies that require efficient compound screening and lead optimization. HitGen's offerings include the research and creation of DEL technology, development of hit and lead compounds, and transfer of new drug R&D projects. The company's DEL screening services are a core product, allowing clients to identify promising compounds quickly. By focusing on DEL technology, HitGen positions itself as a key provider of specialized services for drug discovery in both domestic and international markets.

Frequently asked questions about HitGen

Analysts currently set an average price target of 27.74 CNY for the HitGen stock (median: 27.74 CNY), implying -23.4 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the HitGen stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect HitGen to generate revenue of 712.29 M CNY and earnings per share of 0.40 CNY.

Converted at the current exchange rate, the HitGen share trades at 3.96 EUR (29.05 CNY).

The expected revenue of HitGen is 712.29 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of HitGen is 159.99 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of HitGen is currently 72.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the HitGen stock.

The price-to-sales ratio (P/S) of HitGen is currently 16.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the HitGen stock.

The Eulerpool Quality Score for HitGen is 5/10.

The ISIN of HitGen is CNE1000040G3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of HitGen is 688222.SS. The ticker symbol is used to trade HitGen shares on the stock exchange.

Fair ValueTerminal
25.85 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
1.03 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website hitgen.com
Country
Currency
CNY
Initial public offering
Apr 16, 2020
ISIN
CNE1000040G3
Cusip
Y322GW103
Market capitalization
11.64 B CNYLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
72.75
P/Ee 2027
53.33
P/Ee 2028
—
P/Ee 2029
—
P/Ee 2030
—
P/Se
16.34
EV/EBIT
84.03
P/B Ratio
7.75
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.68 %
Dividend
Dividend yield
0.21 %
Est. Dividend Yield
0.45 %
Payout Ratio
21.95 %
Dividend growth Ø5Y
21.06 %
Dividend payments per year
1
Dividend paid since
2 years
Dividend not reduced since
2 years
Dividend increased since
2 years
Dividend withholding tax
10.00 %
Last updated Nov 19, 2026, 3:41 AM

HitGen Peer Group

HitGen FIGI

688222:CG · BBG00PNX8F13688222:CH · BBG00L1B3LF1688222:C1 · BBG01GZT7FP3

All fundamentals and in-depth analysis of HitGen

Our stock analysis for HitGen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HitGen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.